Skip to main content
  • MEETINGS
  • JOBS/RFPs
  • FUNDING
 

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

Home

Bioengineering technology for fast optical control of differentiation and function in stem cells and stem cell progeny

Bioengineering technology for fast optical control of differentiation and function in stem cells and stem cell progeny

Karl Deisseroth
Stanford University
New Faculty I: RN1-00535-1
Status: Active
$3154719.00

The New Faculty Awards are intended to encourage and support the next generation of clinical and scientific leaders in stem cell research. The 22 awards given out on 12/12/07 in the first round of these awards were worth $55,426,401. You can learn more about the awards by reading the RFA or reading the press release.

Public Abstract (provided by applicant)

Embryonic stem (ES) cells potentially could provide clinically important replacement tissue for central nervous system (CNS) disease treatment, and regenerative medicine approaches involving ES cells have been suggested for common CNS disorders. But it has been difficult to produce the right kind of replacement tissues from ES cells because the "differentiation", or cell-type specification process, takes many days to weeks, during which time many different stimuli and signaling molecules need to be physically applied to the stem cells. This process of "stem cell differentiation" is slow, costly, laborious, variable, prone to error and contamination, and ultimately rate-limiting in the long road leading to clinical translation. We propose to develop and apply fast, inexpensive, and robust optical technologies to the fundamental problem of stem cell differentiation and regenerative medicine, with particular focus on CNS disease.

Statement of benefit to California (provided by applicant)

Neuropsychiatric diseases like Parkinson's disease and major depression are leading causes of disability and death in California and worldwide. They are difficult to treat, poorly understood, and devastating for patients, families, and society as a whole. Our proposed fusion of engineering technology with clinically-inspired stem cell technology represents a unique opportunity, which we anticipate will lead not only to fundamentally new, potent, and specific therapies for diseases representing major burdens for the state, but also to engineering and medical commercial ventures that will add resources, money, and skilled jobs to the robust and growing state economy.

Newsletter Sign-Up

Receive press releases, funding announcements or other news from CIRM.

>> Click here to sign up

Follow Us

Facebook Updates
YouTube Videos
Twitter
Flickr Images
LinkedIn
Research Blog
RSS Feeds

 

« May 2012 »
MonTueWedThuFriSatSun
123456
78910111213
14151617181920
21222324252627
28293031
Bookmark and Share
  • Contact Us
  • Privacy Policy
  • Accessibility
  • Site Map
© 2009 California Institute For Regenerative Medicine